In 2019, Siddiqi et al. [31] reported the preliminary data of their phase 1/2 PLATFORM study (within the TRANSCEND NHL 001 trial, NCT02631044) [32], evaluated liso-cel in combination with durvalumab (anti-PD-L1 antibody) in patients with R/R B-NHL. The gene discussed is CD274; the disease is non-Hodgkin lymphoma.